Eterna Therapeutics Inc (ERNA) Stock Price, Quote & News

Company Profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. Th...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 798 6700

Website: www.ernexatx.com

Address:

1035 Cambridge Street, Suite 18A, Cambridge, United States

UnoffensiveName May. 8 at 9:05 PM

$ERNA Heres the timeline IND filing — Q3 2026 Request permission to begin human trials. Phase 1 (Safety/Dose Finding) — Late 2026 to 2027 First humans treated. Main goal: safety, toxicity, dosing. Phase 2 (Early Efficacy) — 2028–2029 Does it actually shrink ovarian tumors meaningfully in patients? Phase 3 (Large Confirmatory Trial) — 2030–2032 Large randomized trial versus standard treatment. Possible FDA Approval — Earliest roughly 2032–2033 Only if efficacy and safety remain strong throughout.

0 · Reply

UnoffensiveName May. 8 at 8:49 PM

$ERNA wonder if itll work on humans?

0 · Reply

SadyK189 May. 8 at 8:22 PM

Here is my Amazing daily "Stocktwits" report: $RXT $PMAX $ERNA $SGML $MASK RXT Price at 2.40. My post was "Looking good on daily chart. Key support at 1.65 - 1.80. Next key level to test 2.85 - 3.05." It made a MASSIVE move to 6.00 today MASK Price at 2.28. My post was "Good close of 4hours candle. Key support at 1.55 - 1.70. Next key level to test 2.85 - 3.10." It made a nice move to 3.78 today PMAX Price at 4.34. My post was "Looking good on 4hours chart. Key support at 3.10 - 3.40. Next key level to test 5 - 5.40." It hit our desired zone, went till 5.38 today ERNA Price at 6.74. My post was "Looking good on 4hours chart. Key support at 5.30 - 5.65. Next key level to test 7.8 - 8.15." It hit our desired zone, went till 8.66 today SGML Price 17.35. My post was" SGML is trending nicely on daily chart. Key support at 14.20 - 14.70. Next key level to test 18.9 - 19.55." It went till 23.77 today

0 · Reply

marketmoney402 May. 8 at 8:00 PM

$ERNA Nice, strong closing above VWAP (with bullish momentum). Daily chart still strong. Expecting continuation but may sell & take profits if it dips too low in AH/PM.

0 · Reply

HazelNewton May. 8 at 7:27 PM

$ERNA low liquidity setup, bids need to stay firm or spread takes over

0 · Reply

jackedmund99 May. 8 at 6:46 PM

$ERNA building a new base great action it’s better have to stop take two steps up and sit down and be flat for a while that just makes the move bigger and bigger later on.

0 · Reply

Game_Day May. 8 at 6:19 PM

MAY 8 current watchlist 📊 $UBER $WYNN $ERNA $EL $BKNG Follow for great stocks watch ideas 💵

0 · Reply

RhinoResurrected May. 8 at 5:57 PM

$ERNA

0 · Reply

globaldaytraderzzz May. 8 at 5:55 PM

$ERNA can we get $9.50 by bell yesss

0 · Reply

Pidxr May. 8 at 5:33 PM

$ERNA steamroller setting up. Did anyone not load up extra shares this AM ?

0 · Reply

Ernexa Therapeutics initiated with a Buy at Brookline

2026-05-07T16:17:11.000Z - 1 day ago

3 Penny Stocks to Watch Now, 5/7/26

AHMA PMAX

2026-05-07T04:27:19.000Z - 1 day ago

Ernexa Therapeutics announces new ERNA-101 preclinical data

May 6, 2026, 8:33 AM EDT - 2 days ago

Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models

2026-04-30T19:19:12.000Z - 8 days ago

Ernexa Therapeutics announces 1-for-25 reverse stock split

Apr 30, 2026, 9:00 AM EDT - 8 days ago

Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split

Mar 31, 2026, 8:55 AM EDT - 5 weeks ago

Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026

2026-03-16T10:56:34.000Z - 7 weeks ago

Ernexa Therapeutics files $50M mixed securities shelf

Feb 20, 2026, 9:05 AM EST - 2 months ago

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

2026-02-06T14:30:30.000Z - 3 months ago

Ernexa Therapeutics prices 21M shares at 50c in public offering

Feb 6, 2026, 9:25 AM EST - 3 months ago

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

Feb 3, 2026, 8:45 AM EST - 3 months ago

Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

2026-02-03T11:21:14.000Z - 3 months ago

Ernexa Therapeutics files to sell common stock, warrants, no amount given

2026-01-27T13:52:07.000Z - 3 months ago

Ernexa selected as company for JETRO Japan entry acceleration program

Jan 27, 2026, 8:45 AM EST - 3 months ago

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

2026-01-06T13:38:50.000Z - 4 months ago

Ernexa Therapeutics completes Pre-IND meeting with FDA

Jan 6, 2026, 8:15 AM EST - 4 months ago

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

2025-12-08T13:40:52.000Z - 5 months ago

Ernexa Therapeutics presents preclinical data at ASH meeting on ERNA-101

Dec 8, 2025, 8:30 AM EST - 5 months ago

Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer

Dec 3, 2025, 8:30 AM EST - 5 months ago

Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting

2025-12-02T13:55:30.000Z - 5 months ago

Ernexa Therapeutics appoints Ira Winer to Scientific, Medical Advisory Board

Dec 2, 2025, 8:50 AM EST - 5 months ago

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D.

Nov 11, 2025, 7:00 AM EST - 6 months ago

Ernexa Therapeutics to Present at Oxford Global's Cell 2025

2025-11-10T13:40:53.000Z - 6 months ago

Ernexa Therapeutics reports Q3 operating loss $2M vs $2.3M last year

Nov 10, 2025, 8:35 AM EST - 6 months ago

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

Nov 6, 2025, 9:15 AM EST - 6 months ago

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

2025-10-29T12:35:32.000Z - 6 months ago

Ernexa Therapeutics, Cellipont Bioservices enter collaboration

Oct 29, 2025, 8:33 AM EDT - 6 months ago

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Oct 1, 2025, 8:30 AM EDT - 7 months ago

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

Sep 29, 2025, 8:30 AM EDT - 7 months ago

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

Sep 17, 2025, 8:30 AM EDT - 8 months ago

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

2025-09-10T12:35:19.000Z - 8 months ago

Ernexa Therapeutics reports 1H operational loss $5.4M vs $10.7M last year

Sep 10, 2025, 8:30 AM EDT - 8 months ago

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

Sep 3, 2025, 9:30 AM EDT - 8 months ago

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

2025-07-09T12:40:48.000Z - 10 months ago

Ernexa Therapeutics regains compliance with Nasdaq listing rules

Jul 9, 2025, 8:30 AM EDT - 10 months ago

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

2025-06-25T12:41:45.000Z - 11 months ago

Ernexa Therapeutics expands Scientific Advisory Board

Jun 25, 2025, 8:30 AM EDT - 11 months ago

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

2025-06-24T12:46:06.000Z - 11 months ago

Ernexa secures $6M in second closing under securities purchase agreement

Jun 24, 2025, 8:30 AM EDT - 11 months ago

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Jun 10, 2025, 9:30 AM EDT - 11 months ago

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

May 28, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

May 8, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Apr 22, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Apr 3, 2025, 8:55 AM EDT - 1 year ago

Ernexa Therapeutics Closes New Funding Round

Feb 26, 2025, 8:30 AM EST - 1 year ago

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Jan 14, 2025, 8:30 AM EST - 1 year ago

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Jan 9, 2025, 7:30 AM EST - 1 year ago

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Nov 14, 2024, 8:30 AM EST - 1 year ago

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Oct 17, 2024, 8:00 AM EDT - 1 year ago

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

May 10, 2024, 8:00 AM EDT - 2 years ago

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

May 8, 2024, 9:31 AM EDT - 2 years ago

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Feb 20, 2024, 8:30 AM EST - 2 years ago

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Jan 3, 2024, 4:15 PM EST - 2 years ago

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Dec 20, 2023, 4:15 PM EST - 2 years ago

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Dec 14, 2023, 6:56 PM EST - 2 years ago

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

Nov 1, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

Sep 5, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors

Jul 11, 2023, 8:30 AM EDT - 3 years ago

Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors

May 24, 2023, 8:30 AM EDT - 3 years ago

Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel

May 17, 2023, 8:30 AM EDT - 3 years ago

Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 4, 2023, 8:30 AM EDT - 3 years ago

Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 2, 2023, 7:30 AM EDT - 3 years ago

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

UnoffensiveName May. 8 at 9:05 PM

0 · Reply

UnoffensiveName May. 8 at 8:49 PM

$ERNA wonder if itll work on humans?

0 · Reply

SadyK189 May. 8 at 8:22 PM

0 · Reply

marketmoney402 May. 8 at 8:00 PM

$ERNA Nice, strong closing above VWAP (with bullish momentum). Daily chart still strong. Expecting continuation but may sell & take profits if it dips too low in AH/PM.

0 · Reply

HazelNewton May. 8 at 7:27 PM

$ERNA low liquidity setup, bids need to stay firm or spread takes over

0 · Reply

jackedmund99 May. 8 at 6:46 PM

$ERNA building a new base great action it’s better have to stop take two steps up and sit down and be flat for a while that just makes the move bigger and bigger later on.

0 · Reply

Game_Day May. 8 at 6:19 PM

MAY 8 current watchlist 📊 $UBER $WYNN $ERNA $EL $BKNG Follow for great stocks watch ideas 💵

0 · Reply

RhinoResurrected May. 8 at 5:57 PM

$ERNA

0 · Reply

globaldaytraderzzz May. 8 at 5:55 PM

$ERNA can we get $9.50 by bell yesss

0 · Reply

Pidxr May. 8 at 5:33 PM

$ERNA steamroller setting up. Did anyone not load up extra shares this AM ?

0 · Reply

RhinoResurrected May. 8 at 5:31 PM

$ERNA

0 · Reply

globaldaytraderzzz May. 8 at 5:28 PM

$ERNA opportunity off lifetime to invest in ,new to world ovarian cancer cure, load heavy nxt up $30

0 · Reply

Russell007xx May. 8 at 5:10 PM

$ERNA 30 dollars? 😂

0 · Reply

SadyK189 May. 8 at 3:48 PM

Mid-Day Update 🚀 🎯 Levels respected perfectly: $RXT → called at 2.40 → went till 5.44 (+127%)🔥 $MASK → called at 2.28 → went till 3.73 (+64%)📈 $PMAX → called at 4.34 → went till 5.38 (+24%)✅ $ERNA → called at 6.74 → went till 8.66 (+28%)🚀 $SGML → called at 17.35 → went till 23.77 (+37%)📈 All levels shared earlier (in detailed posts) and reacting cleanly.

0 · Reply